EUVIMEDFaigh amach EUVIMED
Open access · CC BY 4.0

Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations

Jouni Härkönen, Satu Tiainen, Jouni Kujala, Linnea Muhonen, Ponnuswamy Mohanasundaram, Tuomas Tikkanen, Ina Pöhner iD, Tommi Patinen, Simone Adinolfi, Juha P Väyrynen iD, Päivi Auvinen, Arto Mannermaa and 3 more

The Journal of Pathology · 2026-06 · 269 (2) · 164-181

DOI: 10.1002/path.70043 ↗

At a glance

Journal article in The Journal of Pathology, published online on 2026-03-02. Written by Jouni Härkönen and 14 co-authors. Institution: Faculty of Health Sciences, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland. Major MEDLINE topics: Carcinoma, Non-Small-Cell Lung, NF-E2-Related Factor 2, Lung Neoplasms, Mutation. Cited 1 times so far (Crossref); 65 references. The full text is freely available (open access, CC BY 4.0). Funded by: Sigrid Juséliuksen Säätiö, Paavo Koistinen Foundation, Jane ja Aatos Erkon Säätiö.

AchoimreSubjectsSonraí leabharliostaCiteRelated studies

Abstract (original language)

Lung cancer is the leading cause of global cancer‐related morbidity and mortality, with tobacco smoking as its strongest risk factor. Nuclear factor erythroid 2‐related factor 2 (NRF2) is a redox‐regulated transcription factor frequently dysregulated in non‐small cell lung cancer (NSCLC), leading to aggressive disease and resistance to therapy. In this study, we analyzed circulating cell‐free tumor DNA from a real‐world cohort to characterize clinicopathological features and identify risk factors associated with oncogenic NRF2 activation in inoperable NSCLC. Key findings were further validated using retrospective datasets. Our results demonstrate that NRF2 pathway‐mutated NSCLC represents a smoking‐associated, high‐risk molecular subtype frequently accompanied by detrimental SMARCA4 mutations. Importantly, these co‐occurring mutations cumulatively worsen clinical outcomes independently of other risk factors. We show that NRF2‐mutated tumors generally exhibit lower leukocyte infiltration, while high tumor mutation burden independently correlates with increased cytotoxic T lymphocyte density, regardless of NRF2 status. Furthermore, our data indicate that NRF2 activation can be reliably identified through immunohistochemical detection of protein expression of markers AKR1B10 and AKR1C1, both of which correlate with inferior outcomes. As mutations in NRF2‐regulating tumor suppressors KEAP1 and CUL3 are not confined to specific hotspot regions, our findings advocate for a multimodal profiling approach combining somatic mutation assessment with protein or transcriptomic evaluation of NRF2 targets. This comprehensive strategy effectively identifies oncogenic NRF2 hyperactivity, enhancing diagnostic accuracy and clinical decision‐making in NSCLC management. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Carcinoma, Non-Small-Cell LungNF-E2-Related Factor 2Lung NeoplasmsMutationBiomarkers, TumorHumansFemaleMaleMiddle AgedAgedSignal TransductionTranscription FactorsNuclear ProteinsDNA HelicasesRetrospective StudiesRisk FactorsGenetic Predisposition to DiseaseSmoking

Author keywords

AKR1B10AKR1C1CUL3KEAP1NFE2L2SMARCA4cell‐free DNAcirculating tumor DNAnon‐small cell lung cancertumor microenvironment

Substances

NF-E2-Related Factor 2NFE2L2 protein, humanBiomarkers, TumorTranscription FactorsNuclear ProteinsSMARCA4 protein, humanDNA Helicases

Authors and institutions

  • Faculty of Health Sciences, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
  • Department of Pathology, Hospital Nova, Wellbeing Services County of Central Finland, Jyväskylä, Finland.
  • Cancer Center, Kuopio University Hospital, the Wellbeing Services County of North Savo, Kuopio, Finland.
  • Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland.
  • FICAN East, Kuopio University Hospital, the Wellbeing Services County of North Savo, Kuopio, Finland.
  • Institute of Clinical Medicine, Clinical Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland.

ORCID profiles: Ina Pöhner, Juha P Väyrynen, Anna-Liisa Levonen

Funding

  • Sigrid Juséliuksen Säätiö
  • Paavo Koistinen Foundation
  • Jane ja Aatos Erkon Säätiö
  • University of Eastern Finland Doctoral Program in Molecular Medicine
  • Cancer Foundation Finland
  • Academy of Finland
  • Suomen Kulttuurirahasto
  • Finnish Cultural Foundation

Cite

APA

Härkönen, J., Tiainen, S., Kujala, J., Muhonen, L., Mohanasundaram, P., Tikkanen, T., Pöhner, I., Patinen, T., Adinolfi, S., Väyrynen, J. P., Auvinen, P., Mannermaa, A., Pölönen, P., Rauramaa, T., & Levonen, A. L. (2026). Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations. The Journal of Pathology, 269(2), 164-181. https://doi.org/10.1002/path.70043

Vancouver

Härkönen J, Tiainen S, Kujala J, Muhonen L, Mohanasundaram P, Tikkanen T, et al. Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations. The Journal of Pathology. 2026;269(2):164-181. doi:10.1002/path.70043

BibTeX
@article{Hrknen2026,
  author = {Härkönen, Jouni and Tiainen, Satu and Kujala, Jouni and Muhonen, Linnea and Mohanasundaram, Ponnuswamy and Tikkanen, Tuomas and Pöhner, Ina and Patinen, Tommi and Adinolfi, Simone and Väyrynen, Juha P and Auvinen, Päivi and Mannermaa, Arto and Pölönen, Petri and Rauramaa, Tuomas and Levonen, Anna-Liisa},
  title = {Clinicopathological characteristics of patients with inoperable non‐small cell lung cancer harboring circulating NRF2 pathway mutations},
  journal = {The Journal of Pathology},
  year = {2026},
  volume = {269},
  number = {2},
  pages = {164--181},
  doi = {10.1002/path.70043}
}
Start for free →